We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Endorses Bayer’s Xofigo for Expanded Prostate Cancer Indication
NICE Endorses Bayer’s Xofigo for Expanded Prostate Cancer Indication
The UK’s price watchdog has recommended reimbursement for Bayer’s prostate cancer drug Xofigo for an expanded indication, provided that the company delivers discounted prices as promised.